Who Each Medication Might Suit Patient Profiles Tirzepatide Good Fit If You Want: A well-studied, clinically proven option Steady, predictable fat loss and metabolic support An accessible medication now (current approval and availability) Balanced results with moderate side-effect profile Retatrutide May Be Ideal If You Want: A next-generation therapy with stronger fat-loss potential Deeper metabolic shift and body-composition changes A more aggressive approach and are open to an investigational therapy with close supervision The possibility of enhanced energy expenditure and fat oxidation beyond appetite suppression At Everest, we believe the right choice depends on your goals, health history, metabolic profile, and readiness for advanced care not on hype or trends
The TRIUMPH trials are currently ongoing, and their data will form the evidence base required for regulatory review by the MHRA and EMA
Hair Thinning and Bariatric Patients Bariatric patients have an increased chance of hair loss due to the same reasons- vitamin and mineral deficiencies and protein deficiency
We have spent the last 18 months reading every GLP-1 lean-mass paper we can find and stress-testing the resulting protocol with our own readers
Eli Lilly has also released competing GLP-1 drugs in the form of Mounjaro (tirzepatide), approved for diabetes treatment in 2022, and a weight loss version of the drug was approved by the FDA last year, which is marketed under the brand name Zepbound
GLP-1 medications have long half-lives and bind strongly to proteins in your blood, which means even small amounts can sustain receptor activation over time
.png)
&srotate=0)
